Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Standard Medicines

Drugs

Locations

Clinical Specialty

1341-1360 of 1,782 trials

Chickenpox Vaccine Study for Children Aged 12 to 15 Months

We are evaluating a new chickenpox vaccine to see how well it works and its safety compared to the standard Varivax vaccine in healthy children. This study aims to ensure that the new vaccine provides a strong immune response.

Chickenpox6-12 monthsConfirmation phase (III)≤5 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteInfectious DiseasesPediatrics

Clindamycin for Infections: Impact of Rifampicin and Obesity

We are studying how body weight and the antibiotic rifampicin affect the effectiveness of clindamycin in treating infections. This research may help improve treatment strategies for patients with varying body types.

Hidradenitis SuppurativaProsthetic Joint InfectionsFracture Related Infections≤3 monthsMonitoring phase (IV)No Placebo Standard Medicines Cost ReimbursementInfectious DiseasesInternal Medicine

Small Cell Lung Cancer: Sacituzumab Govitecan vs. Standard Care

We are studying a new treatment called sacituzumab govitecan for patients with previously treated extensive stage small cell lung cancer. The goal is to see if it works better and is safer than current standard treatments.

Extensive Stage Small Cell Lung CancerConfirmation phase (III)≤5 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncology

C3 Glomerulopathy: Aliskiren vs. Enalapril

We are studying whether the medication aliskiren can improve kidney function in people with C3 glomerulopathy compared to the standard treatment, enalapril. This trial aims to assess its safety and effectiveness in reducing kidney disease markers.

C3 Glomerulopathy>2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Standard MedicinesInfectious DiseasesNephrology

Alpha-1 Antitrypsin Deficiency: Prolastin® Self-Infusion Therapy

We are studying the safety of a self-infusion therapy with Prolastin® for patients with severe alpha-1-antitrypsin deficiency. The trial also looks at quality of life and patient satisfaction with this treatment.

Alpha-1 Antitrypsin Deficiency3-6 monthsConfirmation phase (III)>20 visits No Placebo Standard Medicines Partially RemoteInternal MedicinePulmonology

Histiocytosis: Fludeoxyglucose (18F-FDG) Imaging Study

We are examining how fludeoxyglucose (18F-FDG) in PET/CT scans can help monitor juvenile patients with histiocytosis. The study will assess its safety and potential benefits for those with specific mutations.

Erdheim-Chester DiseaseLangerhans Cell SarcomaRosai-Dorfman Syndrome>2 yearsMonitoring phase (IV)No Placebo Standard MedicinesHematologyOtolaryngology

Histiocytosis in Children: Trametinib Study

We are testing the safety and effectiveness of trametinib in children with refractory histiocytosis. The goal is to find the best dosage and timing for treatment after other therapies have failed.

Erdheim-Chester DiseaseRosai-Dorfman SyndromeLangerhans' Cell Histiocytosis>2 yearsEfficacy phase (II)No Placebo Standard MedicinesOncologyPediatrics

Posttraumatic Headache: Botulinum Toxin A Study

We are investigating whether botulinum toxin A can safely reduce the number of headache days for individuals with posttraumatic headaches. The study also looks at biological markers to see if they can predict treatment success.

Post-Traumatic Headache3-6 monthsConfirmation phase (III)≤5 visits Standard Medicines Cost Reimbursement Partially RemoteInternal MedicineNeurology

Chronic Lung Disease in Premature Babies: OHB-607 Study

We are testing a new drug to see if it helps reduce lung disease in extremely premature infants compared to standard care. The study aims to improve their overall health and development.

Chronic Lung Disease6-12 monthsEfficacy phase (II)≤5 visits No Placebo Standard Medicines Cost Reimbursement Partially RemotePediatricsPulmonology

Iptacopan for Pediatric Patients with PNH

We are studying the safety and tolerability of iptacopan in children with PNH. The trial will also evaluate its effects on hemoglobin levels and the need for blood transfusions.

Paroxysmal Nocturnal Hemoglobinuria (PNH)6-12 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteHematologyInternal Medicine

Drug-Resistant Epilepsy: Rapamycin Study

We are investigating whether rapamycin is safe and effective for people with drug-resistant epilepsy due to tuberous sclerosis complex. The study also examines its effects on related neuropsychiatric disorders and tumors.

Tuberous Sclerosis Complex3-6 monthsConfirmation phase (III)>20 visits Post-Trial Drug Access Standard Medicines Partially RemoteInternal MedicineNeurology

Lung Cancer: Pembrolizumab Maintenance Study

We are studying whether continuing pembrolizumab treatment helps patients with stage IV lung cancer maintain disease control after initial chemotherapy. This trial will also look at the quality of life and side effects experienced by participants.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No Placebo Standard MedicinesOncology

Rapamycin for Drug-Resistant Epilepsy in Children

We are studying the safety and effectiveness of rapamycin for children with drug-resistant epilepsy caused by rare central nervous system diseases. This trial aims to find better treatment options for these challenging conditions.

Epilepsy and Related Disorders>2 yearsEfficacy phase (II)No Placebo Standard MedicinesNeurology

High-Grade Glioma in Children: Rapamycin Study

We are evaluating the safety and effectiveness of rapamycin for treating high-grade gliomas in children. This study aims to understand how well it works and if genetic factors play a role in treatment response.

High Grade Glioma>2 yearsEfficacy phase (II)No Placebo Standard MedicinesOncologyPediatrics

Acute Cholecystitis: Antibiotic Treatment Comparison

We are studying whether a single dose of antibiotics before gallbladder surgery is as effective as continuous antibiotics in preventing infections. This trial aims to improve patient outcomes during and after surgery.

Acute Cholecystitis>2 yearsConfirmation phase (III)No Placebo Standard MedicinesGastroenterologyInternal Medicine

Dystonia: Botulinum Toxin for Arm Tremors

We are exploring how different tests and imaging techniques can help determine the effectiveness of botulinum toxin for treating arm tremors in people with dystonia. This study aims to improve treatment options for those affected.

Dystonic Tremor Syndrome6-12 monthsMonitoring phase (IV)≤5 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementNeurology

Oligometastatic Peritoneal Gastric Cancer: PIPAC Treatment Study

We are studying whether adding pressurized intraperitoneal aerosol chemotherapy (PIPAC) to standard chemotherapy helps patients with oligometastatic peritoneal gastric cancer have better surgery outcomes and longer survival.

Metastatic Gastric Adenocarcinoma1-2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Standard MedicinesGastroenterologyOncology

Lung Cancer Treatment: Chemotherapy + Atezolizumab

We are studying a combination of chemotherapy and atezolizumab for patients with stage IIIA and IIIB non-small cell lung cancer. This trial aims to see if this approach improves survival and treatment outcomes before and after surgery.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)No Placebo Standard MedicinesOncology

Cardiac Arrest: Ketamine vs. Propofol Sedation

We are studying whether ketamine sedation can better protect the brain and improve survival compared to propofol in patients resuscitated from cardiac arrest. This trial looks at outcomes at discharge and 180 days later.

Out-of-Hospital Cardiac Arrest1-2 yearsConfirmation phase (III)Monitoring phase (IV)No Placebo Standard Medicines Partially RemoteCardiologyNeurology

Nevoid Basal Cell Carcinoma Syndrome: Sonidegib Treatment Study

We are studying the effects of Sonidegib on patients with Nevoid Basal Cell Carcinoma Syndrome and sporadic basal cell carcinoma. The trial will assess treatment effectiveness, safety, and quality of life improvements.

Nevoid Basal Cell Carcinoma Syndrome6-12 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Standard MedicinesOncology

Search Clinical Trials in the European Union